Jacobio Pharmaceuticals Group Co., Ltd. (1167) AI Stock Analysis

• Market Cap: HK$5.49B
• Dividend Yield: N/A
• Average Volume (3M): 7.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 770.20%
• EPS Growth: 87.27%
• Country: HK
• Employees: 257
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 791,755,070
• 10 Day Avg. Volume: 5,388,349
• 30 Day Avg. Volume: 7,936,853
• PEG Ratio: 0.11
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 5.94
• P/FCF Ratio: -10.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$9.50
• Price Target Upside: 19.20% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$8.00 ▲(0.38% Upside)

The overall stock score is primarily impacted by the company's financial instability, with consistent net losses and poor cash flow metrics. Technical analysis suggests some potential for recovery, but valuation remains weak due to negative earnings. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Strong Cash Position

A strong cash position provides a liquidity buffer, allowing the company to sustain operations and invest in R&D despite financial challenges.

Collaborative Partnerships

Collaborative partnerships can drive innovation and expand market reach, supporting long-term growth through shared expertise and resources.

Revenue Growth

Substantial revenue growth suggests a rebound in business operations, potentially leading to improved financial stability and market confidence.

Negative Factors

Consistent Net Losses

Ongoing net losses indicate challenges in achieving profitability, which can hinder long-term sustainability and investor confidence.

Negative Cash Flow

Negative cash flow suggests difficulties in generating sufficient cash from operations, potentially limiting the ability to fund growth initiatives.

Declining Equity Base

A declining equity base can signal financial instability, reducing the company's ability to absorb losses and secure financing.

Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model

Company Description

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.

How the Company Makes Money

Jacobio Pharmaceuticals generates revenue through several key streams, including the sale of its proprietary drug products once they receive regulatory approval and are commercialized. The company also engages in collaborative partnerships with other pharmaceutical firms, which may involve licensing agreements, joint ventures, or research collaborations that provide upfront payments, milestone payments based on clinical progress, and royalties on future sales. Additionally, Jacobio may receive funding through grants or investments aimed at supporting its research and development efforts, further contributing to its financial growth.

Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview

Summary

Jacobio Pharmaceuticals Group Co., Ltd. faces significant challenges with consistent net losses and operational inefficiencies impacting profitability and cash flow. While a strong cash position provides some liquidity buffer, declining revenue, negative equity history, and poor cash flow metrics highlight financial instability.

Income Statement

The company has experienced significant volatility in revenue, with a notable decline from 2020 to 2023 and some recovery in 2024. Gross profit margin is positive in the latest year, but net profit margin remains negative due to high operating expenses and consistent net losses. The EBIT and EBITDA margins are also unfavorable, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong cash position relative to debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the equity ratio has decreased over time, and the company has reported negative stockholders' equity in previous years, indicating financial instability. The debt-to-equity ratio is manageable, but the declining equity base is a concern.

Cash Flow

The company has struggled with negative operating cash flow and free cash flow over the years, reflecting operational inefficiencies. The lack of free cash flow growth and negative cash flow from operations are significant concerns, although the company maintains a strong cash reserve.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	201.37M	155.71M	63.52M	95.75M	152.81M	486.29M
Gross Profit	201.37M	155.71M	3.20M	12.63M	12.83M	442.17M
EBITDA	-72.93M	-192.36M	-325.73M	-355.80M	-289.83M	-1.50B
Net Income	-45.65M	-155.71M	-359.12M	-371.86M	-301.19M	-1.51B
Balance Sheet
Total Assets	1.29B	1.36B	1.46B	1.57B	1.72B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.07B	1.17B	1.15B	1.28B	1.54B	1.63B
Total Debt	143.01M	152.08M	209.91M	147.79M	6.81M	10.65M
Total Liabilities	423.87M	435.99M	387.11M	292.12M	84.75M	81.15M
Stockholders Equity	867.38M	923.18M	1.07B	1.28B	1.64B	1.79B
Cash Flow
Free Cash Flow	99.69M	-86.21M	-402.86M	-308.92M	-158.63M	67.87M
Operating Cash Flow	106.31M	-74.12M	-364.20M	-292.42M	-147.49M	78.83M
Investing Cash Flow	212.53M	256.22M	-48.00M	-686.32M	161.67M	-215.56M
Financing Cash Flow	-4.48M	21.28M	246.28M	-9.85M	109.06M	1.28B

Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Positive. The current price of 7.97 is above the 20-day moving average (MA) of 7.09, below the 50-day MA of 8.03, and above the 200-day MA of 5.91, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 56.57 is Neutral, neither overbought nor oversold. The STOCH value of 80.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1167.

Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.48B	181.90	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1873	51 Neutral	HK$4.88B	26.46	4.45%	―	-8.11%	―
3681	45 Neutral	HK$2.15B	―	-55.33%	―	-100.00%	30.68%
1167	45 Neutral	HK$5.49B	-109.29	-5.08%	―	770.20%	87.27%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%
2179	39 Underperform	HK$2.78B	―	-129.05%	―	―	-18.99%

Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events

Jacobio Pharmaceuticals Unveils Promising Preclinical Data for Pan-KRAS Inhibitor

Jacobio Pharmaceuticals announced the presentation of preclinical data for their pan-KRAS inhibitor, JAB-23E73, at the AACR-NCI-EORTC 2025 conference. The data indicates that JAB-23E73 shows strong antitumor activity and good tolerability in KRAS-driven cancer models, with ongoing Phase I trials in China and the U.S. This advancement could enhance Jacobio’s position in the oncology sector, potentially impacting stakeholders positively if successful.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Advances Strategic Focus with Capital Increase and Equity Transfer

Jacobio Pharmaceuticals Group Co., Ltd. has announced a capital increase and equity transfer agreement involving its subsidiaries and partners, including Oceanpine Capital. This strategic move allows Jacobio to focus on its core oncology therapies while optimizing capital allocation and enhancing organizational efficiency. The proceeds from the transaction will be used to advance the company’s Pan-KRAS inhibitor and other innovative oncology projects, aligning with its strategic goals and benefiting shareholders.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Announces Shareholding Changes and Share Repurchase Updates

Jacobio Pharmaceuticals Group Co., Ltd. has announced changes in shareholdings among its Concert Parties, with a significant purchase of 11,058,650 shares, reflecting strong confidence in the company’s growth potential and long-term investment value. Additionally, the company has been actively repurchasing its shares on the market, with a total of 326,400 shares bought back, as part of a larger HK$100 million share repurchase plan, indicating the board’s belief that the current share price undervalues the company’s intrinsic worth.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Sees Increase in Concert Party Shareholdings

Jacobio Pharmaceuticals Group Co., Ltd. announced that parties acting in concert with the company have increased their shareholdings by purchasing 402,000 shares on the open market. This move reflects strong confidence in the company’s development prospects and growth potential, with the concert parties now holding approximately 25.41% of the total issued shares. The increase in shareholding is in line with applicable laws and regulations, and further increases are not ruled out.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Reports Significant Progress in Oncology Pipeline for H1 2025

Jacobio Pharmaceuticals announced its interim results for the first half of 2025, highlighting significant progress in its drug pipeline. Key achievements include the market approval of glecirasib for NSCLC patients with KRAS G12C mutations, and promising results from trials involving sitneprotafib and other investigational drugs. The company is advancing its clinical trials in China and the U.S., with ongoing studies in multiple cancer types, including a pivotal Phase II basket study. These developments underscore Jacobio’s commitment to expanding its oncology portfolio and enhancing its market position.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Establishes Nomination Committee to Enhance Governance

Jacobio Pharmaceuticals Group Co., Ltd. has outlined the terms of reference for its Nomination Committee, which was established to review and recommend board appointments and ensure compliance with applicable laws and regulations. The committee will consist mainly of independent non-executive directors, and it will meet at least once annually to fulfill its duties, impacting the company’s governance structure and potentially its strategic direction.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Announces Board Meeting for Interim Results

Jacobio Pharmaceuticals Group Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to consider and approve the interim results for the first half of the year. This meeting is significant as it will address the company’s financial performance and potentially influence its strategic direction and stakeholder interests.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Increases Concert Parties’ Shareholdings

Jacobio Pharmaceuticals Group Co., Ltd. announced that its parties acting in concert have increased their shareholdings by purchasing an additional 60,900 shares on the open market. This move reflects strong confidence in the company’s growth prospects and long-term investment value, with the Concert Parties now holding approximately 25.36% of the total issued shares. The shareholding increase was conducted in compliance with applicable laws and regulations, and there is potential for further increases in the future.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.